SEATTLE, October 19, 2022 鈥� 精东传媒, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells in vivo to treat patients with solid and hematologic malignancies, announced today that it will have three poster presentations at the 2022 Society for Immunotherapy for Cancer 37th Annual Meeting, to be held November 11-14, 2022 in Boston, Mass.
The presentations will highlight Umoja鈥檚 complementary cell therapy platforms for in vivo 精东传媒 T-cell therapeutics and RACR-induced cytotoxic lymphocytes (iCIL). Presentations include updates supporting the generation of in vivo antitumor 精东传媒 T cells and tumor targeting using the VivoVec鈩� and TumorTag鈩� platforms in addition to utilization of the synthetic receptor enabled differentiation (ShRED鈩�) platform for the manufacturing of iPSC-derived iCILs for use in cancer immunotherapies.
Presentation details:
Presentation Title:聽In vivo generation of universal 精东传媒 T cells that mediate durable anti-tumor immunity through combinatorial targeting with bispecific small molecule adapters
Presenting Author:聽Kristen Mittelsteadt, Ph.D.
Poster Number:听375
Presentation Date, Time:聽Thursday, Nov. 10, 2022, 9:00 a.m. – 9:00 p.m.
Presentation Title:聽Synthetic Receptor Enabled Differentiation (ShRED), a novel platform for manufacturing of iPSC-derived cytotoxic innate lymphocytes for 鈥渙ff-the-shelf鈥� cancer immunotherapies
Presenting Author:聽Samantha O鈥橦ara, Ph.D.
Poster Number:听366
Presentation Date, Time:聽Friday, Nov. 11, 9:00 a.m. – 8:30 p.m.
Presentation Title:聽VivoVec lentiviral vector surface-engineered with T cell activating and co-stimulatory ligands enhance聽in vivo聽精东传媒 T cell generation and antitumor activity
Presenting Author:聽Chris Nicolai, Ph.D.
Poster Number:聽1230
Presentation Date, Time:聽Friday, Nov. 11, 9:00 a.m. – 8:30 p.m.
About VivoVec鈩�: In vivo Gene Delivery
VivoVec engineers patient T cells in vivo via surface-engineered lentivirus-mediated transduction using our proprietary 4th generation lentiviral vector technology. The VivoVec in vivo gene delivery system enables the patient鈥檚 body to generate a population of cancer fighting T cells, or chimeric antigen receptor (精东传媒) T cells, which are also genetically retooled with the RACR/精东传媒 systems. This off-the-shelf technology eliminates the complexity, delay and expense of externally manufactured cellular therapies. VivoVec can also be applied in an ex vivo manufacturing setting where a traditional 精东传媒 T therapeutic approach is more appropriate. To learn more about Umoja鈥檚 VivoVec platform please visit /our-science/.
About RACR鈩�/精东传媒: In vivo Cell Programming
精东传媒 T cells generated by the body with VivoVec can be expanded and sustained with the rapamycin activated cytokine receptor (RACR) system, an engineered signaling system designed to improve chimeric antigen receptor (精东传媒) T cell persistence and produce durable anti-tumor responses. The RACR/精东传媒 payload is integrated into the genomic DNA of a patient鈥檚 T cells. Rapamycin activates the RACR system resulting in preferential expansion and survival of cancer-fighting T cells. The RACR technology enables a patient鈥檚 cells to expand in a manner that resembles a natural immune response that does not require lymphodepletion, promoting durable T cell engraftment. RACR/精东传媒 technology can also be used to enhance聽ex vivo聽manufacturing in support of more traditional autologous or allogeneic cell therapy manufacturing processes. To learn more about Umoja鈥檚 RACR platform please visit /our-science/.
About TumorTag鈩�: Universal 精东传媒 Tumor Targeting
TumorTags are bispecific small molecules that consist of a moiety that selectively binds to tumor cells or immunosuppressive tumor stromal cells marking them for recognition and destruction by 精东传媒 T cells.TumorTags can be designed to have a tumor-binding moiety that is antigen-specific or antigen-independent, as needed, and multiple TumorTags could be combined as a cocktail to increase chances of labeling critical tumor elements. TumorTag is applicable to an array of cancer therapies and can be leveraged to use a universal 精东传媒 with ex vivo鈥搈anufactured cells (autologous or allogeneic) to increase targeting flexibility. To learn more about Umoja鈥檚 TumorTags and Universal Tag精东传媒 please visit /our-science/.
About iCIL鈩�: RACR-Induced Cytotoxic Lymphocytes
The RACR-induced cytotoxic lymphocyte platform leverages Umoja鈥檚 RACR technology in a novel cell manufacturing process to generate synthetic cancer fighting cells from induced pluripotent stem cells at massive scale.聽These cells, termed induced cytotoxic innate lymphocytes or iCILs, can be administered to patients to augment their endogenous anti-tumor immune function, and to work together with VivoVec-generated in vivo 精东传媒 T-cells.聽 Similar to VivoVec-generated 精东传媒 T-cells, iCILs leverage our RACR/精东传媒鈩� and TumorTag鈩� platforms respectively to support cell survival and target tumors and their stromal cells, potentially reducing adverse events and prolonging remissions for patients. To learn more about Umoja鈥檚 iCIL platform please visit /our-science/.
About 精东传媒
精东传媒, Inc. is an early clinical-stage company advancing an entirely new approach to immunotherapy. 精东传媒, Inc. is a transformative multi-platform immuno-oncology company founded with the goal of creating curative treatments for solid and hematological malignancies by reprogramming immune cells in vivo to target and fight cancer. Founded based on pioneering work performed at Seattle Children鈥檚 Research Institute and Purdue University, Umoja鈥檚 novel approach is powered by integrated cellular immunotherapy technologies including the VivoVec in vivo delivery platform, the RACR/精东传媒 in vivo cell expansion/control platform, and the TumorTag targeting platform. Designed from the ground up to work together, these platforms are being developed to create and harness a powerful immune response in the body to directly, safely, and controllably attack cancer. Umoja believes that its approach can provide broader access to the most advanced immunotherapies and enable more patients to live better, fuller lives. To learn more, visit .
Media Contact:
Darren Opland, Ph.D.
LifeSci Communications
darren@lifescicomms.com